The U.S. Food and Drug Administration (FDA) is officially incorporating age-related aging into its policies. This means that treatments that slow the aging process could be more readily approved. The FDA announced this at a congress on aging research, where top scientists also discussed new therapies.
Ageing is the process by which the body slowly deteriorates on a physical and mental level. This increases the risk of multiple diseases at the same time. Because the FDA is now focusing on ageing as a topic, future medicines can now be officially tested for their effect on this decline. This is a new step, as previously, mainly individual conditions were examined.
Several methods are being investigated to prove that a treatment slows down aging. For example, a drug can be shown to reduce several age-related diseases. It is also possible to look at the overall functioning of older people, such as their strength and mental health. The goal is to clearly demonstrate that the drug works well for older people.
Finding good markers remains an important challenge. These are signs in the body that indicate health or the aging process. If they are reliable, examinations can be conducted more quickly and efficiently. The FDA encourages collaboration between researchers and companies to develop and use these markers together.
For people who want to become healthier as they age, this is good news. It means that more attention and funding will soon be given to medications that can improve the quality of life in old age and slow down the aging process. This can contribute to a healthier and longer life.
Source: Arkadi Mazin
